抗纤维化药物治疗慢性肾脏病:综述
该综述讨论直接靶向肾脏纤维化治疗慢性肾脏病的概念与实践挑战,指出纤维化是否为慢性肾脏病进展的原因或结果尚存争议。常规临床缺乏评估全肾纤维化的工具,多数临床前抗纤维化药物同时作用于多条致病通路。吡非尼酮正在开展针对肾纤维化的2期试验,其他用于或正在测试用于特发性肺纤维化的药物也可能是候选药物。
要点
- 肾脏纤维化是慢性肾脏病的标志和潜在治疗靶点,但直接靶向纤维化存在概念与实践挑战。
- 纤维化是慢性肾脏病进展的原因还是结果尚有争议,常规临床缺乏评估全肾纤维化的工具。
- 未来靶向肾纤维化的药物应证明对标准治疗有额外获益,标准治疗包括肾素-血管紧张素系统联合盐皮质激素受体阻断或联合钠/葡萄糖协同转运蛋白2抑制剂。
核心结论
- 肾脏纤维化是慢性肾脏病的标志和潜在治疗靶点,但直接靶向肾脏纤维化存在概念和实践挑战。
- 未来靶向肾脏纤维化的药物应证明对标准治疗有额外获益,标准治疗联合肾素-血管紧张素系统与盐皮质激素受体阻断或与钠/葡萄糖协同转运蛋白2抑制剂。
研究设计与样本
- 综述,讨论抗纤维化药物治疗慢性肾脏病的概念与实践挑战及候选药物。
主要发现
- 纤维化是慢性肾脏病进展的主要原因还是结果尚有争议。
- 多数临床前模型中减少纤维化的药物同时靶向其他且常常是多条致病通路,如肾素-血管紧张素-醛固酮系统阻断。
- 常规临床实践中缺乏评估全肾纤维化的工具。
- 吡非尼酮正在开展针对肾纤维化的2期试验。
- 其他用于或正在测试用于特发性肺纤维化的药物如尼达尼布、PRM-151、表没食子儿茶素没食子酸酯也可能是治疗肾纤维化的候选药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, there are conceptual and practical challenges to directly targeting kidney fibrosis. Whether fibrosis is mainly a cause or a consequence of CKD progression has been disputed. It is unclear whether specifically targeting fibrosis is feasible in clinical practice because most drugs that decrease fibrosis in preclinical models target additional and often multiple pathogenic pathways (eg, renin-angiotensin-aldosterone system blockade). Moreover, tools to assess whole-kidney fibrosis in routine clinical practice are lacking. Pirfenidone, a drug used for idiopathic pulmonary fibrosis, is undergoing a phase 2 trial for kidney fibrosis. Other drugs in use or being tested for idiopathic pulmonary fibrosis (eg, nintedanib, PRM-151, epigallocatechin gallate) are also potential candidates to treat kidney fibrosis. Novel therapeutic approaches may include antagomirs (eg, lademirsen) or drugs targeting interleukin 11 or NKD2 (WNT signaling pathway inhibitor). Reversing the dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a standard of care that combines renin-angiotensin system with mineralocorticoid receptor (eg, finerenone) blockade or with sodium/glucose cotransporter 2 inhibitors.
引用
- Ruiz-Ortega M, Lamas S, Ortiz A, et al. Antifibrotic Agents for the Management of CKD: A Review. Am J Kidney Dis. 2022. PMID: 34999158. doi:10.1053/j.ajkd.2021.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。